報價延遲最少15分鐘:2025/03/28 08:24 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.14 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.60/-1.34
|
|
企業價值
175.09M
|
| 資產負債 |
|
每股賬面淨值
0.95
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/28 08:24 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis. |